Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Novartis Ag ADR(NVS-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low156.18
Day High160.54
Open:156.71
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Novartis Ag ADR

Select a category then submit the form to load news
Zacks Investment Research
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Zacks Investment Research
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Motley Fool
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Motley Fool
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
Motley Fool
Could Novartis Stock Quietly Help You Build a Millionaire Retirement Portfolio?
Motley Fool
Arvinas (ARVN) Q4 2025 Earnings Call Transcript
Motley Fool
Stock Market Today, Feb. 23: Novo Nordisk Plunges 16% After Obesity Drug Falls Short
Motley Fool
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Tipranks
Jefferies Reaffirms Their Hold Rating on Novartis AG (NOVN)
Motley Fool
Promethos Capital Liquidates $4 Million Sprouts Farmers Market Position: Should Investors Sell, Too?
Motley Fool
Buy 2 Vanguard Index Funds to Beat the S&P 500 in the Next Decade, According to Wall Street Analysts
Tipranks
Novartis AG (NOVN) Receives a Buy from Deutsche Bank
Zacks Investment Research
International ETFs to Watch as Foreign Stock Markets Beat the US
International ETFs to Watch as Foreign Stock Markets Beat the US
Tipranks
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
Tipranks
Novartis Earnings Call: Record Margins Amid Generic Wave
Zacks Investment Research
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?
Newswire.ca
Kisqali® Receives Positive Draft Recommendation From Canada's Drug Agency For All Eligible Early Breast Cancer Patients at High Risk of Recurrence
Motley Fool
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript
Tipranks
Novartis AG (NOVN) Gets a Buy from Deutsche Bank
Tipranks
Barclays Remains a Hold on Novartis AG (NOVN)
Tipranks
Novartis Faces Mounting ESG and Sustainability Risks That Could Weigh on Reputation, Financing, and Long-Term Value
Motley Fool
Novartis (NVS) Q3 2024 Earnings Call Transcript
Tipranks
UBS Sticks to Its Hold Rating for Novartis AG (NOVN)
Tipranks
Novartis Files 2025 Annual and Nonfinancial Reports with U.S. SEC
Tipranks
Novartis Posts Strong 2025 Results and Pipeline Wins as It Enters Major Patent-Expiry Year
Tipranks
Novartis AG (NOVN) Gets a Sell from Goldman Sachs
Tipranks
Jefferies Remains a Hold on Novartis AG (NOVN)
Zacks Investment Research
ADP Payrolls Come in Way Below Expectations
ADP Payrolls Come in Way Below Expectations
Zacks Investment Research
ADP Jobs Lower, Q4 Earnings Reports Up
ADP Jobs Lower, Q4 Earnings Reports Up
Zacks Investment Research
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Healthcare ETFs to Watch as Novo Nordisk Tumbles on Poor Sales Outlook
Zacks Investment Research
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales
Motley Fool
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook

Profile

Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.